Literature DB >> 19625466

Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene.

Virginie Williams1,2, Ségolène Brichler1,2, Nadjia Radjef2, Pierre Lebon3, Anne Goffard4, Didier Hober4, Remi Fagard5, Dina Kremsdorf1, Paul Dény6,2, Emmanuel Gordien1,2.   

Abstract

Co-infection and superinfection of hepatitis B virus (HBV) with hepatitis delta virus (HDV) leads to suppression of HBV replication both in patients and in animal and cellular models. The mechanisms behind this inhibition have not previously been explored fully. HBV replication is governed by four promoters and two enhancers, Enh1 and Enh2. Repression of these enhancers has been reported to be one of the main mechanisms of HBV inhibition. Moreover, in a previous study, it has been demonstrated that alpha interferon (IFN-alpha)-inducible MxA protein inhibits HBV replication. HDV encodes two proteins, p24 and p27. p27 was shown to activate several heterologous promoters, including HBV promoters. In an attempt to analyse the mechanisms of HBV inhibition by HDV, the question was raised whether HDV proteins could act directly by repressing HBV enhancers, and/or indirectly by activating the MxA gene. This issue was addressed in a co-transfection model in Huh-7 cells, using p24- or p27-expressing plasmids along with Enh1, Enh2, HBV and MxA promoter-luciferase constructs. Enh1 and Enh2 were strongly repressed, by 60 and 80 % and 40 and 60 %, by p24 and p27, respectively. In addition, p27 was responsible for threefold activation of the MxA promoter and potentiation of IFN-alpha on this promoter. MxA mRNA quantification and a virus yield reduction assay confirmed these results. In conclusion, this study shows that HDV proteins inhibit HBV replication by trans-repressing its enhancers and by trans-activating the IFN-alpha-inducible MxA gene.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19625466     DOI: 10.1099/vir.0.011239-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  34 in total

1.  Current concept in the pathophysiology of hepatitis delta infection.

Authors:  Grazia Anna Niro; Antonina Smedile
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

Review 2.  Life cycle and pathogenesis of hepatitis D virus: A review.

Authors:  Zaigham Abbas; Rafia Afzal
Journal:  World J Hepatol       Date:  2013-12-27

3.  Molecular interactions between hepatitis B virus and delta virus.

Authors:  Elham Shirvani-Dastgerdi; Frank Tacke
Journal:  World J Virol       Date:  2015-05-12

Review 4.  Hepatitis D virus coinfection and superinfection.

Authors:  Francesco Negro
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

Review 5.  Controversies in hepatitis C therapy: Reactivation of hepatitis B virus.

Authors:  Sarah R Lieber; Michael W Fried
Journal:  Clin Liver Dis (Hoboken)       Date:  2017-10-31

6.  Hepatitis D Virus: A Call to Screening.

Authors:  Joseph Ahn; Robert G Gish
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-10

Review 7.  Hepatitis D and hepatocellular carcinoma.

Authors:  Zaigham Abbas; Minaam Abbas; Sarim Abbas; Lubna Shazi
Journal:  World J Hepatol       Date:  2015-04-18

8.  Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.

Authors:  Jeremie Guedj; Yaron Rotman; Scott J Cotler; Christopher Koh; Peter Schmid; Jeff Albrecht; Vanessa Haynes-Williams; T Jake Liang; Jay H Hoofnagle; Theo Heller; Harel Dahari
Journal:  Hepatology       Date:  2014-10-27       Impact factor: 17.425

9.  Treatment options for hepatitis delta virus infection.

Authors:  Benjamin Heidrich; Michael P Manns; Heiner Wedemeyer
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

Review 10.  Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead.

Authors:  Heiner Wedemeyer; Michael P Manns
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.